 |
- goat polyclonal IgG, 200 µg/ml
- epitope mapping at the N-terminus of Evi-1 of human origin
- recommended for detection of Evi-1 of human origin by WB, IP, IF and ELISA; also reactive with additional species, including equine, canine, bovine, porcine and avian
- blocking peptide, sc-8706 P
- TransCruz reagent for Gel Supershift and ChIP applications, sc-8706 X, 200 µg/0.1 ml
|
|
| |
Ordering Information
Recommended Support Products:
(click button of application of choice)
| |
| Species |
Gene Name |
Gene ID |
Chromosome Location |
Isoform (mRNA) Accession # |
Protein Accession # |
OMIM™ Number |
| Human |
EVI1 |
2122 |
3q26.2 |
NM_005241 |
Q03112
|
n/a |
| Mouse |
Evi1 |
14013 |
3 A3 |
|
P14404
|
N/A |
| |
Evi-1 Background Information The Evi-1 proto-oncogene contains two zinc finger domains, the second of which is essential for transactivation of the c-Fos promoter and for AP-1 activation. The first zinc finger domain binds to Smad3, suppressing its activity and inhibiting TGF∫ signaling. The t(3;21) (q26;q22) chromosomal translocation produces a chimeric transcription factor, AML-1/Evi-1, that appears to suppress the transactivation of AML-1, which is a stimulator of myeloid cell differentiation. Inappropriate Evi-1 gene expression in hemato-poietic cells has been shown to be associated with acute myelogenous leukemia (AML) and myelodysplastic syndromes.
|
 |
|
Evi-1 (N-20)
Click on image to enlarge
|
|
Evi-1 (N-20): sc-8706. Western blot analysis of Evi-1 expression in Hep G2 whole cell lysate.
|
|
Download
|
|